Usana Health Sciences Inc SEC Filings

USANA Health Sciences (USNA) reported a director’s acquisition of 1,057 shares of common stock on 10/23/2025, coded “M” for settlement of restricted stock units.

After the transaction, the reporting person beneficially owns 1,057 shares directly and 2,115 restricted stock units. The RSUs vest 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.

USANA Health Sciences (USNA) disclosed an insider transaction by a director on 10/23/2025. The filing reports the acquisition of 1,057 shares of common stock via the settlement of restricted stock units (Transaction Code M). Following the transaction, the reporting person directly owns 6,315 common shares and holds 2,115 restricted stock units.

The RSUs vest in four equal installments of 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026. The RSU settlement carried a stated price of $0 for the underlying common shares, consistent with equity award vesting mechanics.

USANA Health Sciences (USNA) disclosed insider activity dated 10/23/2025. A director acquired 1,057 shares of common stock through the conversion of restricted stock units (code M) and disposed of 476 shares (code F) at $20.63.

After the transactions, the director beneficially owned 5,918 common shares directly and held 2,115 restricted stock units. These RSUs vest 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.

USANA Health Sciences furnished an update on investor communications. The company announced a press release with financial results for the third quarter ended September 27, 2025, and said it will post a “Management Commentary” on its website. Executives will host a conference call with brief remarks followed by Q&A, with webcast and telephone access details provided.

The press release and Management Commentary are included as Exhibits 99.1 and 99.2 and are furnished, not filed. These materials will be available on www.usana.com.

Dimensional Fund Advisors LP reports holding 915,049 shares of USANA Health Sciences Inc common stock, representing 5.0% of the class. The filing states that the reported shares are owned by investment funds advised or sub‑advised by Dimensional, which disclaims beneficial ownership and says the holdings are managed in the ordinary course of business and not for the purpose of changing or influencing control. Of the reported shares, Dimensional asserts sole voting power over 887,817 shares and sole dispositive power over 915,049 shares; no shared voting or dispositive power is reported.

The statement clarifies these holdings arise from Dimensional’s advisory roles to registered investment companies, commingled funds, group trusts and separate accounts and that no single Fund listed is known to hold more than 5% of the class. The filing includes the required certification by Dimensional’s compliance officer.

Myron W. Wentz, a director and >10% owner of USANA Health Sciences (USNA), reported a sale of 145,000 shares of Common Stock. After the reported disposition, the filing shows beneficial ownership of 7,408,345 shares held indirectly through Gull Global Limited, an entity Dr. Wentz indirectly owns and controls. The filing also explains Gull Global Limited is owned 50% by Viron Company Limited and 50% by Myogen Limited, each ultimately controlled by Dr. Wentz. The disclosure is limited to the change in share count and the ownership chain; no option or derivative transactions are reported.

USANA Health Sciences (USNA) filer submitted a Form 144 proposing the sale of 5,169 common shares through Morgan Stanley Smith Barney on the NYSE. The shares have an aggregate market value of $165,408 and the issuer reports 18,271,836 shares outstanding, making the sale a small fraction of total shares. The shares were acquired as restricted stock in early February 2025 (944 on 02/07/2025, 2,805 on 02/08/2025 and 1,420 on 02/06/2025) and the approximate sale date is listed as 08/28/2025. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.

Gilbert A. Fuller, a director of USANA Health Sciences Inc (USNA), reported a sale of 1,058 shares of common stock on 08/07/2025 at approximately $29.1014 per share. The Form 4 lists the transaction as a sale and shows 0 shares beneficially owned by Fuller following the reported transaction, with ownership held directly. The filing discloses the required Section 16 details for the transaction.